Literature DB >> 27511964

Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.

Elizabeth Stinson1, Le'Kneitah P Smith1, Kelly Stefano Cole1, Eileen M Barry2, Douglas S Reed3.   

Abstract

Tularemia is a severe, zoonotic disease caused by a gram-negative bacterium, Francisella tularensis We have previously shown that rabbits are a good model of human pneumonic tularemia when exposed to aerosols containing a virulent, type A strain, SCHU S4. We further demonstrated that the live vaccine strain (LVS), an attenuated type B strain, extended time to death when given by scarification. Oral or aerosol vaccination has been previously shown in humans to offer superior protection to parenteral vaccination against respiratory tularemia challenge. Both oral and aerosol vaccination with LVS were well tolerated in the rabbit with only minimal fever and no weight loss after inoculation. Plasma antibody titers against F. tularensis were higher in rabbits that were vaccinated by either oral or aerosol routes compared to scarification. Thirty days after vaccination, all rabbits were challenged with aerosolized SCHU S4. LVS given by scarification extended time to death compared to mock-vaccinated controls. One orally vaccinated rabbit did survive aerosol challenge, however, only aerosol vaccination extended time to death significantly compared to scarification. These results further demonstrate the utility of the rabbit model of pneumonic tularemia in replicating what has been reported in humans and macaques as well as demonstrating the utility of vaccination by oral and respiratory routes against an aerosol tularemia challenge. © FEMS 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  live attenuated vaccines; mucosal vaccination; respiratory disease; tularemia

Mesh:

Substances:

Year:  2016        PMID: 27511964      PMCID: PMC5968310          DOI: 10.1093/femspd/ftw079

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  41 in total

1.  Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine.

Authors:  H T EIGELSBACH; J J TULIS; E L OVERHOLT; W R GRIFFITH
Journal:  Proc Soc Exp Biol Med       Date:  1961-12

2.  Aerogenic immunization of man with live Tularemia vaccine.

Authors:  R B Hornick; H T Eigelsbach
Journal:  Bacteriol Rev       Date:  1966-09

3.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

4.  Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Authors:  Amanda J Griffin; Deborah D Crane; Tara D Wehrly; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

5.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

6.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

Review 7.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

8.  Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.

Authors:  J J Drabick; R B Narayanan; J C Williams; J W Leduc; C A Nacy
Journal:  Am J Med Sci       Date:  1994-08       Impact factor: 2.378

Review 9.  Animal models of Francisella tularensis infection.

Authors:  C Rick Lyons; Terry H Wu
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

10.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

View more
  8 in total

1.  Development, Characterization, and Standardization of a Nose-Only Inhalation Exposure System for Exposure of Rabbits to Small-Particle Aerosols Containing Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Eileen M Barry; Karsten R O Hazlett; Douglas S Reed
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

Review 2.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

3.  Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models.

Authors:  José Carlos Solana; Laura Ramírez; Laura Corvo; Camila Indiani de Oliveira; Manoel Barral-Netto; José María Requena; Salvador Iborra; Manuel Soto
Journal:  PLoS Negl Trop Dis       Date:  2017-05-30

4.  Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.

Authors:  Alison A McCormick; Aisha Shakeel; Chris Yi; Hardeep Kaur; Ahd M Mansour; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

Review 5.  Adaptive Immunity to Francisella tularensis and Considerations for Vaccine Development.

Authors:  Lydia M Roberts; Daniel A Powell; Jeffrey A Frelinger
Journal:  Front Cell Infect Microbiol       Date:  2018-04-06       Impact factor: 5.293

6.  Identification of an Attenuated Substrain of Francisella tularensis SCHU S4 by Phenotypic and Genotypic Analyses.

Authors:  Julie A Lovchik; Douglas S Reed; Julie A Hutt; Fangfang Xia; Rick L Stevens; Thero Modise; Eileen M Barry; Terry H Wu
Journal:  Pathogens       Date:  2021-05-22

7.  Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Elizabeth Stinson; Kelly S Cole; Barbara J Mann; Prachi Namjoshi; Karsten R O Hazlett; Eileen M Barry; Douglas S Reed
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

8.  Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment.

Authors:  Adva Mechaly; Uri Elia; Ron Alcalay; Hila Cohen; Eyal Epstein; Ofer Cohen; Ohad Mazor
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.